{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:15:18Z","timestamp":1764170118684,"version":"3.46.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>TAFRO syndrome, characterised by thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly, is a rare subtype of idiopathic multicentric Castleman disease. Although it is generally not associated with autoimmune diseases, cases with systemic lupus erythematosus have been reported. We report a case of a 52-year-old male with systemic lupus erythematosus complicated by TAFRO syndrome-like conditions. The patient had persistent thrombocytopenia, renal dysfunction, and fluid retention refractory to glucocorticoids, IL-6 inhibitors, and plasma exchange. Treatment with cyclosporine and belimumab was initiated due to a suspicion of aberrant B-cell activation, resulting in a 2-year remission without relapse. To explore the immunological pathogenesis, CXCL13 and BAFF levels were analysed during the clinical course. Despite interleukin-6 (IL-6) inhibitor therapy, C\u2013X\u2013C motif chemokine ligand 13 (CXCL13) levels remained elevated, suggesting the involvement of an alternative regulatory pathway. Both CXCL13 and B-cell activating factor (BAFF) levels decreased after treatment with cyclosporine and belimumab, and this correlated with clinical improvement. CXCL13, which is produced by peripheral helper T cells, promotes aberrant B-cell activation and lymphoid tissue formation. Meanwhile, BAFF supports B-cell survival and autoreactivity, acting alongside CXCL13 to sustain pathological B-cell activity. This case highlights the importance of therapies targeting T-cell and B-cell interactions in certain diseases with refractory conditions. Additionally, monitoring CXCL13 and BAFF may help optimise therapeutic strategies. Combination therapy with cyclosporine and belimumab effectively suppressed both cytokines, achieving sustained disease control. Future studies should utilise cytokine profiling, including CXCL13 and BAFF, to establish personalised therapeutic strategies in cases of systemic lupus erythematosus presenting with TAFRO syndrome-like conditions.<\/jats:p>","DOI":"10.1093\/mrcr\/rxaf063","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T12:29:43Z","timestamp":1762777783000},"source":"Crossref","is-referenced-by-count":0,"title":["A case of systemic lupus erythematosus complicated by TAFRO syndrome-like conditions: analysis of C\u2013X\u2013C motif chemokine ligand 13 and B-cell activating factor dynamics and the efficacy of combination therapy with cyclosporine and belimumab"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3641-2723","authenticated-orcid":false,"given":"Shotaro","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Allergology, St Marianna University School of Medicine , Kanagawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5555-1019","authenticated-orcid":false,"given":"Yukiko","family":"Takakuwa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergology, St Marianna University School of Medicine , Kanagawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Ishizaki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergology, St Marianna University School of Medicine , Kanagawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergology, St Marianna University School of Medicine , Kanagawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-345X","authenticated-orcid":false,"given":"Seido","family":"Ooka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergology, St Marianna University School of Medicine , Kanagawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-9987","authenticated-orcid":false,"given":"Kimito","family":"Kawahata","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergology, St Marianna University School of Medicine , Kanagawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"2025112610120644300_ref1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s12185-016-1979-1","article-title":"Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version","volume":"103","author":"Masaki","year":"2016","journal-title":"Int J Hematol"},{"key":"2025112610120644300_ref2","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1038\/s41598-024-53413-5","article-title":"TAFRO syndrome is associated with anti-SSA\/Ro60 antibodies, in contrast to idiopathic Castleman disease","volume":"14","author":"Shirakashi","year":"2024","journal-title":"Sci Rep"},{"key":"2025112610120644300_ref3","doi-asserted-by":"publisher","first-page":"103137","DOI":"10.1016\/j.autrev.2022.103137","article-title":"TAFRO syndrome: a severe manifestation of Sjogren\u2019s syndrome? A systematic review","volume":"21","author":"Grange","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2025112610120644300_ref4","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/ajh.25123","article-title":"Plasma proteomics identifies a \u2018chemokine storm\u2019 in idiopathic multicentric Castleman disease","volume":"93","author":"Pierson","year":"2018","journal-title":"Am J Hematol"},{"key":"2025112610120644300_ref5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"2025112610120644300_ref6","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"2025112610120644300_ref7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/2193-1801-3-349","article-title":"Bone marrow fibrosis as a feature of systemic lupus erythematosus: a case report and literature review","volume":"3","author":"Chalayer","year":"2014","journal-title":"Springerplus."},{"key":"2025112610120644300_ref8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1046\/j.1440-1827.2000.01052.x","article-title":"Reactive follicular hyperplasia in the lymph node lesions from systemic lupus erythematosus patients: a clinicopathological and immunohistological study of 21 cases","volume":"50","author":"Kojima","year":"2000","journal-title":"Pathol Int"},{"key":"2025112610120644300_ref9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1177\/0961203317725589","article-title":"Characterization of patients with systemic lupus erythematosus who meet the diagnostic criteria for TAFRO syndrome","volume":"27","author":"Hasegawa","year":"2018","journal-title":"Lupus"},{"key":"2025112610120644300_ref10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3960\/jslrt.21037","article-title":"International definition of iMCD-TAFRO: future perspectives","volume":"62","author":"Nishimura","year":"2022","journal-title":"J Clin Exp Hematop"},{"key":"2025112610120644300_ref11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/mrcr\/rxac045","article-title":"Mimic or coincidentally? TAFRO syndrome and systemic lupus erythematosus: a case-based review","volume":"7","author":"Okyar","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"2025112610120644300_ref12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/0961203317699288","article-title":"Acute acalculous cholecystitis in patients with systemic lupus erythematosus: a unique form of disease flare","volume":"26","author":"Yang","year":"2017","journal-title":"Lupus"},{"key":"2025112610120644300_ref13","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.2169\/internalmedicine.0267-22","article-title":"Acute abdomen and adrenal swelling as the first manifestations of TAFRO syndrome","volume":"62","author":"Fujimi","year":"2023","journal-title":"Intern Med"},{"key":"2025112610120644300_ref14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3960\/jslrt.20065","article-title":"Fatal case of TAFRO syndrome with unilateral adrenal hemorrhage in early-stage disease","volume":"61","author":"Okamoto","year":"2021","journal-title":"J Clin Exp Hematop"},{"key":"2025112610120644300_ref15","doi-asserted-by":"publisher","first-page":"905.e1","DOI":"10.1016\/j.crad.2017.05.007","article-title":"CT findings in 11 patients with TAFRO syndrome: a variant of multicentric Castleman's disease","volume":"72","author":"Kiguchi","year":"2017","journal-title":"Clin Radiol"},{"key":"2025112610120644300_ref16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/mrcr\/rxad020","article-title":"Combined B-cell immunomodulation with rituximab and belimumab in severe, refractory TAFRO syndrome associated with Sj\u00f6gren\u2019s syndrome: a case report","volume":"7","author":"Watanabe","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"2025112610120644300_ref17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/24725625.2020.1789304","article-title":"Sequential change in serum VEGF levels in a case of tocilizumab-resistant TAFRO syndrome treated effectively with rituximab","volume":"5","author":"Wakiya","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"2025112610120644300_ref18","doi-asserted-by":"publisher","first-page":"11255","DOI":"10.3390\/cimb46100668","article-title":"Pathophysiology, treatment, and prognosis of thrombocytopenia, anasarca, fever, reticulin fibrosis\/renal failure, and organomegaly (TAFRO) syndrome: a review","volume":"46","author":"Kakutani","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"2025112610120644300_ref19","doi-asserted-by":"publisher","first-page":"sfae110","DOI":"10.1093\/ckj\/sfae110","article-title":"Long-term clinicopathological characteristics of TAFRO syndrome and its relapse: a case series study","volume":"17","author":"Yoshimura","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025112610120644300_ref20","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025112610120644300_ref21","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1016\/S2665-9913(23)00091-7","article-title":"Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study","volume":"5","author":"Rodziewicz","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025112610120644300_ref22","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/art.42620","article-title":"Comparative risks of infection with belimumab versus oral immunosuppressants in patients with nonrenal systemic lupus erythematosus","volume":"75","author":"Materne","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025112610120644300_ref23","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.1038\/s41467-022-34873-7","article-title":"CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease","volume":"13","author":"Pierson","year":"2022","journal-title":"Nat Commun"},{"key":"2025112610120644300_ref24","doi-asserted-by":"publisher","first-page":"152563","DOI":"10.1016\/j.prp.2019.152563","article-title":"The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome","volume":"215","author":"Kurose","year":"2019","journal-title":"Pathol Res Pract"},{"key":"2025112610120644300_ref25","doi-asserted-by":"publisher","first-page":"6959","DOI":"10.1038\/s41467-023-42718-0","article-title":"Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease","volume":"14","author":"Harada","year":"2023","journal-title":"Nat Commun"},{"key":"2025112610120644300_ref26","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1182\/blood-2007-03-081232","article-title":"BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells","volume":"111","author":"Badr","year":"2008","journal-title":"Blood"},{"key":"2025112610120644300_ref27","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1126\/science.289.5481.883","article-title":"Lymphocyte survival--ignorance is BLys","volume":"289","author":"La\u00e2bi","year":"2000","journal-title":"Science"},{"key":"2025112610120644300_ref28","doi-asserted-by":"publisher","first-page":"e163030","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxaf063\/65269225\/rxaf063.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf063\/65269225\/rxaf063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf063\/65269225\/rxaf063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:12:14Z","timestamp":1764169934000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxaf063\/8320499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxaf063","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rxaf063"}}